TFP
AMED

Tilia Fiduciary Partners’s Amedisys AMED Stock Holding History

Tilia Fiduciary Partners’s Portfolio AMED Stock Details AMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-204
Closed -$18.7K – 110
2023
Q2 		$18.7K Sell
204
-3,228
-94% -$265K 0.02% 307
2023
Q1 		$252K Sell
3,432
-2,615
-43% -$226K 0.24% 93
2022
Q4 		$505K Sell
6,047
-279
-4% -$25.2K 0.49% 64
2022
Q3 		$590K Buy
6,326
+897
+17% +$107K 0.6% 53
2022
Q2 		$662K Buy
5,429
+282
+5% +$36K 0.63% 50
2022
Q1 		$887K Buy
5,147
+120
+2% +$17.9K 0.75% 45
2021
Q4 		$814K Buy
+5,027
New +$808K 0.65% 50

Other funds holding AMED

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Tilia Fiduciary Partners's AMED Position: Q3 2023 in Review

Tilia Fiduciary Partners sold out of Amedisys (AMED) in Q3 2023, closing a stake of 204 shares — an estimated $18.7K sold.

Tilia Fiduciary Partners first reported a position in AMED in Q4 2021 and held it in 7 quarters. The position peaked at $887K in Q1 2022. 287 funds tracked by Wall St. Rank hold AMED as of Q3 2023.

  • Tilia Fiduciary Partners reported no remaining Amedisys position as of Q3 2023 after selling out during the quarter.
  • Tilia Fiduciary Partners sold 204 Amedisys shares in Q3 2023, an estimated $18.7K.
  • Tilia Fiduciary Partners first reported a position in Amedisys in Q4 2021 and held it in 7 quarters.
  • Tilia Fiduciary Partners's Amedisys position peaked at $887K in Q1 2022.
  • 287 funds tracked by Wall St. Rank held Amedisys as of Q3 2023.

Based on Tilia Fiduciary Partners's 13F filing for Q3 2023, filed 10 Oct 2023.